ERBB2 and breast carcinoma: Using the human breast cancer cell line SK-BR-3, it was demonstrated that the expression of Pnck accelerated the progression of the cell cycle and increased the proliferation rate of these cells in addition to inducing enhanced cell survival and resistance to trastuzumab, a monoclonal antibody against ErbB2 used in the clinic [94].